Short-term Intravenous Iron Isomaltose Anhydride for IDA

Launched by WEST CHINA HOSPITAL · Apr 11, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating how a short-term treatment with intravenous iron isomaltose anhydride can help improve recovery after orthopedic surgery for patients suffering from iron deficiency anemia (IDA). The goal is to see if this treatment can reduce the need for blood transfusions after surgery, making recovery easier and more effective for patients.

To be eligible for this study, participants need to be at least 15 years old and willing to sign a consent form to join. However, those who are pregnant, have a history of severe allergic reactions to iron, or have certain medical conditions affecting their nervous system will not be able to participate. The study hasn't started recruiting participants yet, but once it does, those who join will receive the iron treatment and will be monitored to see how well it helps them recover after their surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 14 years;
• • Sign and date the "informed consent form"
• Exclusion Criteria:
• • Pregnant or lactation;
• • Drug abuse, including but not limited to opioids, amphetamines, ice, ketamine, etc.;
• • History of anaphylaxis to oral or intravenous iron;
• • Nervous system diseases such as peripheral neuropathy, mental illness;
• • Other conditions that the investigator deems are not suitable for the study, such as deafness, Parkinson's disease, communication disorders, etc.;
• • Participated in other clinical trials during the first three months of the study.